A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (mPDAC).
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Philippa Corrie, Wendi Qian, Bristi Basu, Juan W. Valle, Stephen Falk, Chinenyu Iwuji, Harpreet Singh Wasan, Daniel H. Palmer, Martin Scott-Brown, Jonathan Wadsley, Seema Safia Arif, John A. Bridgewater, David Propper, Roopinder Gillmore, Aarthi Gopinathan, Lisa Bax, Andrea Machin, Albrecht Neesse, David A. Tuveson, Duncan Ian Jodrell
Institutions: Addenbrooke's Hospital, The Christie NHS Foundation Trust, Hammersmith Hospital, Imperial College London, University of Liverpool, University Hospital Coventry, University Hospitals Coventry and Warwickshire NHS Trust, Weston Park Cancer Centre, Velindre Cancer Centre, University College London, St Bartholomew's Hospital, The Royal Free Hospital, Cancer Research UK, Cancer Research UK Cambridge Center, Universitätsmedizin Göttingen, Cold Spring Harbor Laboratory
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4235841716